Cancer Family
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm
CI-CAN-00000039Explore in graph →
Non-malignant864 active trials6 approved drugs159 evidence items
- NCIt
- C35562
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000039Explore in graph →
Clinical trials
3,131 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02287428 | Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM | active not recruiting | Phase 1 | 56 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06126744 | Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252(PuMP) | recruiting | Phase 1 | 51 | Duke UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07185880 | A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients(STAR-GBM) | recruiting | Phase 1 / Phase 2 | 36 | Myosin Therapeutics Inc.INDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04185038 | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | recruiting | Phase 1 | 90 | Seattle Children's HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04528680 | Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma(SC9/ABX) | active not recruiting | Phase 1 / Phase 2 | 57 | Northwestern UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05168423 | CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM | active not recruiting | Phase 1 | 67 | University of PennsylvaniaOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06159166 | Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).(Mirda) | recruiting | Phase 1 / Phase 2 | 24 | Johns Hopkins UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06810544 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | recruiting | Phase 1 / Phase 2 | 191 | Tango Therapeutics, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07134842 | A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.(WinGlio-ipi) | recruiting | Phase 1 | 16 | University College, LondonOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06517888 | Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma | recruiting | Phase 1 / Phase 2 | 27 | Akouos, Inc.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05789394 | Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy | recruiting | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03596086 | HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM | recruiting | Phase 1 / Phase 2 | 62 | David Baskin MDOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03603405 | HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM | recruiting | Phase 1 / Phase 2 | 62 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07431216 | A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression | not yet recruiting | Phase 1 / Phase 2 | 68 | Starlight Therapeutics Inc.INDUSTRY | 0 | Mar 30, 2026 | clinicaltrials |
| NCT03605550 | A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma | active not recruiting | Phase 1 | 64 | Nationwide Children's HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02586857 | A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) | active not recruiting | Phase 1 / Phase 2 | 24 | Acerta Pharma BVINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05413304 | Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis | active not recruiting | Phase 1 | 1 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06482905 | Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. | recruiting | Phase 1 | 52 | Tcelltech Inc.INDUSTRY | 2 | Mar 24, 2026 | clinicaltrials |
| NCT06763965 | Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. | enrolling by invitation | Phase 1 / Phase 2 | 30 | Beijing Bio-Targeting Therapeutics Technology Co., LtdINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07126990 | Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma | enrolling by invitation | Phase 1 / Phase 2 | 40 | Xiaorong WuINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07481721 | IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody for Recurrent Malignant Glioma(APIC-RG) | not yet recruiting | Phase 1 | 24 | Ming YangOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03478462 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas(CLOVER-2) | active not recruiting | Phase 1 | 30 | Cellectar Biosciences, Inc.INDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT05610891 | Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG | active not recruiting | Phase 1 | 50 | Cellectar Biosciences, Inc.INDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
| NCT07480941 | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma(DUAL-CAR-NK-GB) | recruiting | Phase 1 | 36 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04943848 | rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG | recruiting | Phase 1 | 36 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT03749187 | BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas(PNOC017) | active not recruiting | Phase 1 | 78 | University of California, San FranciscoOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05484622 | Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma | active not recruiting | Phase 1 | 60 | Institut de Recherches Internationales ServierOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06504381 | DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma | recruiting | Phase 1 / Phase 2 | 70 | University of California, San FranciscoOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04420975 | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | active not recruiting | Phase 1 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05660408 | RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors(RNA PRIME) | active not recruiting | Phase 1 / Phase 2 | 36 | University of FloridaOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07457307 | Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac(INSIGHT MRL) | not yet recruiting | Phase 1 | 20 | NYU Langone HealthOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07455045 | A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG) | not yet recruiting | Phase 1 | 40 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04661384 | Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | active not recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06917885 | CUE-102 in Recurrent Glioblastoma | recruiting | Phase 1 | 18 | David Reardon, MDOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03152318 | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2(rQNestin) | active not recruiting | Phase 1 | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07438860 | Fluorescence-Guided Imaging of Brain Tumors: A Safety Study Using SBK2-ICG | not yet recruiting | Phase 1 | 12 | Tiffany HodgesOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07318818 | A Clinical Trial of P134 Cells in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 26 | Tasly Pharmaceutical Group Co., LtdINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04606316 | Surgical Nivolumab And Ipilimumab For Recurrent GBM | active not recruiting | Phase 1 | 63 | Patrick Wen, MDOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06342908 | A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma | active not recruiting | Phase 1 | 6 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07218367 | Phase I Trial of pH Resections of GBM at VA | not yet recruiting | Phase 1 | 12 | VA Office of Research and DevelopmentFED | 1 | Feb 13, 2026 | clinicaltrials |
| NCT04478279 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Sapience TherapeuticsINDUSTRY | 2 | Feb 9, 2026 | clinicaltrials |
| NCT06650163 | Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors | recruiting | Phase 1 | 20 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07391215 | 5G-PEARL: Paxalisib in Malignant Brain Tumours(5G-PEARL) | recruiting | Phase 1 / Phase 2 | 64 | Institute of Cancer Research, United KingdomOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03389230 | Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma | active not recruiting | Phase 1 | 29 | City of Hope Medical CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07385846 | Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency | not yet recruiting | Phase 1 | 8 | Jennifer LeddonOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05762419 | FUS Etoposide for DMG | recruiting | Phase 1 | 10 | Columbia UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04196413 | GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG) | recruiting | Phase 1 | 97 | Stanford UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 17, 2026source: clinicaltrials